Quest Diagnostics initiated with a Neutral at UBS. UBS analyst Kevin Caliendo started Quest Diagnostics with a Neutral rating and $90 price target.
Thursday, January 17, 2019
Owens & Minor initiated at UBS
Owens & Minor initiated with a Neutral at UBS. UBS analyst Kevin Caliendo started Owens & Minor with a Neutral rating and $8 price target.
Dentsply Sirona initiated at UBS
Dentsply Sirona initiated with a Neutral at UBS. UBS analyst Kevin Caliendo started Dentsply Sirona with a Neutral rating and $43 price target.
Becton Dickinson reports preliminary Q1 adj. EPS $2.70, consensus $2.62
Reports preliminary Q1 revenue $4.16B, consensus $4.12B.
Aerpio Pharmaceuticals completes patient dosing in 2b study
Aerpio Pharmaceuticals announced the completion of patient dosing in the Company’s TIME-2b study, a Phase 2b clinical trial designed to assess the efficacy and safety of Aerpio’s lead candidate, AKB-9778, for patients with moderate to severe non-proliferative diabetic retinopathy. The TIME-2b study is a double-masked, placebo-controlled, multi-center trial evaluating the effect of AKB-9778 in 167 patients with moderate to severe NPDR. Patients were randomized to receive 48 weeks of treatment with either AKB-9778 15 mg subcutaneously once daily, AKB-9778 15 mg subcutaneously twice daily, or placebo subcutaneously twice daily. The primary endpoint of the TIME-2b study is the percentage of patients who improve by 2 or more steps in diabetic retinopathy severity score in the study eye. One of the secondary objectives, the urine albumin to creatinine ratio or UACR, was prospectively included based on a post-hoc analysis of this biomarker in the TIME-2 Phase 2a clinical trial of AKB-9778. Initial results from this trial are expected in March 2019.
Zafgen: 1.8mg ZGN-1061 dose showed greater efficacy than 0.9mg dose in trial
Zafgen announced data for the second cohort of its Phase 2 clinical trial of ZGN-1061, designed to evaluate efficacy and safety in patients with type 2 diabetes and the likely therapeutic dose range of ZGN-1061 up to 1.8 mg. The clinical trial met all of its primary objectives at the 1.8 mg dose, which included glycemic control, or change in A1C, and safety and tolerability. The 12-week data demonstrated that treatment with the 1.8 mg dose of ZGN-1061 produced substantially more improvement in A1C than the 0.9 mg dose. Progressive and notable reduction in body weight also occurred in patients treated with the 1.8 mg dose. The data showed a favorable safety and tolerability profile for ZGN-1061, with no treatment-related serious adverse events and no cardiovascular safety signals observed. Treatment with ZGN-1061 demonstrated a statistically significant reduction in A1C for 0.9 mg and 1.8 mg versus placebo at Week 12, with a 1.1% reduction in A1C at the 1.8 mg dose relative to placebo. A1C levels continued to decline with no waning of effect for both doses through Week 12. Progressive weight reduction was also observed at the 1.8 mg dose, with placebo-corrected weight loss of 2.3 kg seen at Week 12 with no evidence of waning effect. Significant improvements were observed across multiple secondary efficacy endpoints and various relevant metabolic biomarkers, as well.
Array BioPharma initiated at Leerink
Array BioPharma initiated with an Outperform at Leerink. Leerink analyst Thomas Smith started Array BioPharma with an Outperform rating and $28 price target. The analyst sees Braftovi and Mektovi as a best-in-class combination launching into a $1B global market for the treatment of BRAF+ melanoma, with near-term potential to expand into BRAF+ colorectal cancer, where there is limited competition. Smith also sees a favorable catalyst path for shares through 2019, and believes the company is well-positioned to benefit from the recent resurgence of M&A in the targeted oncology sector.
https://thefly.com/landingPageNews.php?id=2850153
Subscribe to:
Posts (Atom)